Molecular structure of 2-(2-Methylaminoethyl)pyridine, CAS Number: 5638-76-6
2-(2-Methylaminoethyl)pyridine (CAS 5638-76-6)
Alternate Names:
Betahistine
Application:
2-(2-Methylaminoethyl)pyridine is a histidine analog and H1 receptor agonist
CAS Number:
5638-76-6
Purity:
≥95%
Molecular Weight:
136.19
Molecular Formula:
C8H12N2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
2-(2-Methylaminoethyl)pyridine is a strong affinity histamine H3 receptor antagonist and weak affinity agonist of histamine H1 receptors.
2-(2-Methylaminoethyl)pyridine (CAS 5638-76-6) References
- Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. | Lacour, M. and Sterkers, O. 2001. CNS Drugs. 15: 853-70. PMID: 11700150
- Long-term prophylactic treatment of attacks of vertigo in Menière's disease--comparison of a high with a low dosage of betahistine in an open trial. | Strupp, M., et al. 2008. Acta Otolaryngol. 128: 520-4. PMID: 18421605
- Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. | Redon, C., et al. 2011. J Clin Pharmacol. 51: 538-48. PMID: 20940335
- Synthesis and characterization of new chromium, molybdenum and tungsten complexes of 2-[2-(methylaminoethyl)] pyridine. | Ali, SA., et al. 2012. Spectrochim Acta A Mol Biomol Spectrosc. 94: 164-8. PMID: 22513171
- Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. | Deng, C., et al. 2012. J Psychopharmacol. 26: 1271-9. PMID: 22695490
- Effect of standard-dose Betahistine on endolymphatic hydrops: an MRI pilot study. | Gürkov, R., et al. 2013. Eur Arch Otorhinolaryngol. 270: 1231-5. PMID: 22760844
- Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. | Lacour, M. 2013. J Vestib Res. 23: 139-51. PMID: 24177346
- Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). | Adrion, C., et al. 2016. BMJ. 352: h6816. PMID: 26797774
- Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study. | Parfenov, VA., et al. 2017. PLoS One. 12: e0174114. PMID: 28358888
- Betahistine Treatment in a Cat Model of Vestibular Pathology: Pharmacokinetic and Pharmacodynamic Approaches. | Tighilet, B., et al. 2018. Front Neurol. 9: 431. PMID: 29942281
- Betahistine-induced vascular effects in the rat cochlea. | Laurikainen, EA., et al. 1993. Am J Otol. 14: 24-30. PMID: 8424471
- The vascular mechanism of action of betahistine in the inner ear of the guinea pig. | Laurikainen, E., et al. 1998. Eur Arch Otorhinolaryngol. 255: 119-23. PMID: 9561856
Inhibitor of:
Histamine H3 Receptor.Activator of:
Histamine H1 Receptor.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
2-(2-Methylaminoethyl)pyridine, 5 g | sc-254040 | 5 g | $101.00 |